Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:40:09 30/04/2024 BST			5-day change	1st Jan Change
220 ^CHF	-0.52%		-4.05%	-9.86%

04-29	Swiss Equities Close in Red Amid Inflation Spotlight	MT
04-29	Roche Holding AG: slimming down

ROCHE HOLDINGS AG : Deutsche Bank reaffirms its Neutral rating

December 02, 2022 at 10:57 am

Initially Neutral on the company, Deutsche Bank's analyst Emmanuel Papadakis maintained his recommendation. The target price is unchanged and still at CHF 300.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ROCHE HOLDING AG	220 CHF	-0.52%	-4.05%	196B
	DEUTSCHE BANK AG	14.99 EUR	-0.73%	-2.86%	31.89B

Latest news about Roche Holding AG

Swiss Equities Close in Red Amid Inflation Spotlight	04-29	MT
Roche Holding AG: slimming down	04-29
Roche: positive opinion from CHMP for subcutaneous Ocrevus	04-29	CF
European Medicines Agency Committee Backs Roche's Subcutaneous Injection for Multiple Sclerosis	04-29	MT
Roche: positive CHMP opinion for Alecensa	04-26	CF
Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU	04-26	MT
The specter of stagflation rears its ugly head again	04-25
ROCHE : Barclays lowers target price	04-25	CF
Scholz pledges further support for the pharmaceutical industry	04-25	DP
ROCHE HOLDINGS AG : UBS remains Neutral	04-25	ZD
ROCHE HOLDINGS AG : Barclays sticks Neutral	04-25	ZD
Scholz promises support for pharma sector in Germany as Merck invests	04-25	RE
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	04-25	MT
ROCHE HOLDINGS AG : DZ Bank reiterates its Buy rating	04-24	ZD
Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red	04-24	MT
ROCHE HOLDING : In line quarterly results won’t cut it for Roche	04-24
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	04-24
Transcript : Roche Holding AG, Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	04-24
ROCHE HOLDINGS AG : Barclays remains Neutral	04-24	ZD
ROCHE HOLDINGS AG : UBS reaffirms its Neutral rating	04-24	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	04-24	RE
Roche Eyes Potential M&A Deals Amid Pipeline Restructure	04-24	MT
Shares jump on tech boost; fragile yen on intervention watch	04-24	RE
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	04-24	ZD
Roche Sees Return to Growth Ahead After Forex, Post-pandemic Slump Hit First-quarter Sales	04-24	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

14/05/2024 - BofA Securities Health Care Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 04:50 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

221.2 CHF

Average target price

279.4 CHF

Spread / Average Target

+26.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-9.86%	196B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+24.82%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.98%	234B
NOVARTIS AG	+4.62%	199B
AMGEN INC.	-4.04%	148B
PFIZER, INC.	-10.94%	145B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Deutsche Bank reaffirms its Neutral rating

Stocks mentioned in the article

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals